NATCO Pharma has announced that its wholly-owned Canadian subsidiary, NATCO Pharma (Canada) Inc., has made an investment of USD 8 million in eGenesis, Inc., a biotechnology company at the forefront of xenotransplantation focused on developing safe and e?ective human-compatible-organs for transplant.

In March 2024, eGenesis announced the world’s first porcine kidney transplant in a living patient. The transplant was authorized by the US Food & Drug Administration (FDA) under the Expanded Access pathway.

eGenesis is a genome engineering-based approach to develop safe and e?ective transplantable organs to end the global organ shortage and transform the treatment of organ failure.

The eGenesis Genome Engineering and Production (EGEN) Platform is the only technology to comprehensively address cross-species molecular incompatibilities and viral risk via genetic engineering to improve the lives of patients in need of a transplant. eGenesis is advancing development programs for kidney transplant, acute liver failure, and heart transplants.

“We are excited to get involved with eGenesis, Inc. concerning their pioneering work in xeno-transplantation. We agree with the vision of eGenesis that xenotransplantation technology has the potential to end the global transplant shortage and transforming the treatment of organ failure by eliminating waitlist mortality,” said Rajeev Nannapaneni, Vice Chairman and CEO of NATCO Pharma Ltd.

“We are thrilled to welcome NATCO as an investor. Their support will be used in advancing our research and bringing our innovative therapies to market,” said Mike Curtis, CEO of eGenesis, Inc.